& Forbes Holdings Inc.Perel... Net Worth

The estimated Net Worth of & Forbes Holdings Inc.Perel... is at least $28.9 Milhão dollars as of 30 September 2009. Perel owns over 3,851,969 units of SIGA Technologies Inc stock worth over $28,928,287 and over the last 15 years sold SIGA stock worth over $0.

Perel SIGA stock SEC Form 4 insiders trading

has made over 1 trades of the SIGA Technologies Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently bought 3,851,969 units of SIGA stock worth $24,036,287 on 30 September 2009.

The largest trade 's ever made was buying 3,851,969 units of SIGA Technologies Inc stock on 30 September 2009 worth over $24,036,287. On average, trades about 770,394 units every 0 days since 2009. As of 30 September 2009 still owns at least 3,851,969 units of SIGA Technologies Inc stock.

You can see the complete history of Perel stock trades at the bottom of the page.

Insiders trading at SIGA Technologies Inc

Over the last 21 years, insiders at SIGA Technologies Inc have traded over $65,185,125 worth of SIGA Technologies Inc stock and bought 6,065,626 units worth $33,817,674 . The most active insiders traders include Holdings Incperelman Ronald..., Pharma Inc Transtech, eAdnan M M Mjalli. On average, SIGA Technologies Inc executives and independent directors trade stock every 36 days with the average trade being worth of $1,122,865. The most recent stock trade was executed by Dennis E Hruby on 1 July 2024, trading 32,258 units of SIGA stock currently worth $242,258.

What does SIGA Technologies Inc do?

at siga, we specialize in developing therapeutic solutions for some of the most lethal pathogens – smallpox, ebola, dengue, lassa fever and other dangerous viruses. our objective is to discover, develop, and commercialize drugs to prevent and treat these high-priority threats.

Complete history of Perel stock trades at SIGA Technologies Inc

SIGA Technologies Inc executives and stock owners

SIGA Technologies Inc executives and other stock owners filed with the SEC include:

• Daniel Luckshire,
  Chief Financial Officer, Executive Vice President, Secretary
• Dr. Phillip Louis Gomez III, M.D., Ph.D.,
  CEO & Director
• Phillip Gomez,
  Chief Executive Officer, Director
• Robin Abrams,
  Chief Administrative Officer, General Counsel
• Dr. Dennis E. Hruby,
  Exec. VP & Chief Scientific Officer
• Dennis Hruby,
  Chief Scientific Officer, Vice President
• Daniel J. Luckshire,
  Exec. VP, CFO & Sec.
• Robin E. Abrams,
  Gen. Counsel & Chief Admin. Officer
• Eric Rose,
  Chairman of the Board
• Julie Kane,
  Independent Director
• Michael Plansky,
  Independent Director
• Joseph Marshall,
  Independent Director
• James Antal,
  Independent Director
• Thomas Constance,
  Independent Director
• Herb Vloedman,
  Chief Information Officer
• Tove C. Bolken,
  Sr. VP of Operations & Chief Supply Chain Officer
• Diem Nguyen,
  Chief Executive Officer
• Larry R. Miller,
  General Counsel
• Holdings Incperelman Ronald...,
  
• Bruce Slovin,
  Director
• Paul G Savas,
  
• Jeffrey B Kindler,
  
• Scott M Hammer,
  Director
• Donald G Drapkin,
  Director
• Bernard L Kasten,
  Chief Executive Officer
• Ayelet Dugary,
  Acting Chief Financial Officer
• Judy S Slotkin,
  Director
• Michael Md Weiner,
  Director
• Thomas N Konatich,
  CFO, Secretary and Treasurer
• Adnan M M Mjalli,
  Director
• John Odden,
  VP - Business Development
• Ronald O Mac Andrews & Forb...,
  
• William C Bevins,
  Director
• Susan K Burgess,
  President
• Michael J Bayer,
  Director
• Frances F Townsend,
  Director
• William J Ii Haynes,
  Executive VP & General Counsel
• Steven L Fasman,
  Director
• Pharma Inc Transtech,
  10% owner
• & Forbes Holdings Inc.Perel...,
  
• Mehmet C Md Oz,
  Director
• Donald G Drapkin,
  Director
• Evan A. Knisely,
  
• Edward P. Taibi,
  
• Holly L. Phillips,
  
• Jaymie A Durnan,
  
• Gary J. Nabel,
  
• Julian Nemirovsky,
  
• Harold Eugene Jr. Ford,
  
• Jay Varma,
  EVP & Chief Medical Officer